A year ago, when I wrote the editorial for the first issue of Cardiovascular Revascularization Medicine (CRM) for 2020, there was not a clue as to what the year was going to look like. Yes, there were reports on the deadly virus from Wuhan, China, but we were in full plans and preparation to execute the largest Cardiovascular Research Technologies (CRT) meeting ever in February. At that time, no one could imagine that the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) would impact so many lives around the globe, with over 40 million people infected, million deaths, and a global economic meltdown.